AGG Talks: Women in Tech Law Podcast - Episode 4: Preparing for a Transaction? What Emerging Growth Companies Need to Know
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 204: Accelerating Life Sciences Startups with James Chappell of SCbio
Welcome to “Lowenstein Africa Presents: Venture Voices”
A Conversation with Janade du Plessis of Launch Africa Ventures: Balancing Sustainable Development with ROI
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 180: SCBIO and the Life Sciences Industry in South Carolina with James Chappell, SCBIO CEO
Podcast Episode 188: The Power of a Sector Based Approach: Specificity Drives Strategy
A Conversation With Consortium - COVID-19 Client Stories
Life Sciences Quarterly: A View From Washington: What to Expect From the SEC
Ryan Hong Discusses Important Contracts for Startups
Venture Capital Trends: East Meets West – Lewis Geffen, Co-chair, Venture Capital Practice
Financing Challenges for Small Cap Companies
Jaffe Sees 'A Lot' of IPOs in 2013 'Pipeline'
JOBS Act Lessens Disclosure Requirements
In this episode, AGG Corporate partner and member of the firm’s Women in Tech Law, Paula Nagarajan, is joined by Jenea Bradley, an audit partner at Deloitte, to discuss the critical aspects of preparing for a transaction,...more
This Summary does not contain all of the information that you will need to successfully complete your global IPO. You really should read this entire guide as well as the other Latham & Watkins publications referred to in this...more
2023 was a pivotal year for the emerging companies, creating new categories of winners and losers across the board. Emerging companies incorporating artificial intelligence or that have clear line of sight to positive cash...more
On January 30, 2024, McDermott Partners Edward (Jed) Gordon, Kate Vera, and Todd Kornfeld and Associate Allison McSorley Tassel discussed on a panel the current market conditions and shared different capital raising options...more
Mergers, acquisitions, and buyout transactions are complex endeavors requiring careful analysis and consideration of multiple financial inputs and outputs. Both the acquiring company and the target company will each need to...more
History is often written by reference to “before” and “after.” In this blog, we posit that “before” refers to the “bull market” that ended in January 2022, and “after” refers to everything that – happened, is happening, and...more
After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more
This article is the first of a series by the Perkins Coie New Space industry group on developments in the "new space" industry. Responsible for lowering the cost to access space, the "new space" industry has been developing...more
The most frequently asked question at all-hands meetings for a securities offering is “What financial statements will be needed?” The question seems simple enough. But the answer is rarely straightforward. This User’s...more
The most frequently asked question at all-hands meetings for a securities offering is “What financial statements will be needed?” The question seems simple enough. But the answer is rarely straightforward. This User’s Guide...more
Steven Saunders outlines the role of IP in corporate transactions, what investors and acquirers do, how to conduct IP due diligence, how to make your IP stand out, how to drive your IP assets to support your story, how an IP...more
Wilson Sonsini Goodrich & Rosati’s 2019 Mid-Year Technology and Life Sciences IPO Report presents analysis related to the pricing of 49 initial public offerings completed by U.S.-based technology and life sciences issuers...more
With 58 U.S. biopharma IPOs in 2018, the biotech industry entered the new year with confidence. By all appearances, the longest and largest biotech IPO window in history was not going to close anytime soon. ...more
Wilson Sonsini Goodrich & Rosati’s 2018 Technology and Life Sciences IPO Report presents data related to the pricing of 93 IPOs completed by U.S.-based technology and life sciences issuers between January 1 and December 10,...more
Digital health is the convergence between healthcare, genomics, and digital technologies. It is a fast-growing sector with important implications for individuals and institutions alike. Whether it is hospitals and health...more
Four of Latham & Watkins’ leading emerging company partners in Silicon Valley, Luke Bergstrom, Tad Freese, Jim Morrone and JD Marple, recently hosted a webinar titled “Achieving Successful Outcomes as a Non-US Company...more
Because they can…. This was the conclusion of the discussion at the SEC Advisory Committee on Small and Emerging Companies earlier in the week. The Committee discussed statistics relating to the number of companies that are...more
This Glossary is designed to provide law students taking Securities Regulation with a tool that will assist them in learning the basic language of securities law and achieve a working knowledge of the fundamental principles...more
The Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies (Committee) met on June 3 to discuss various topics including (1) SEC rules with respect to intrastate crowdfunding; (2) the...more